Kentaro Tanaka

8PUBLICATIONS
79CO-AUTHORS
Cancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

|Mar 23, 2025
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Kentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi

|Sep 09, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares

|Dec 02, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.

Pasi A Jänne, David Planchard, Kunihiko Kobayashi

Pageof 2